| |
Abstract |
SUMMARY: BMS-790052, Bristol-Myers Squibb’s investigational hepatitis C virus (HCV) NS5A inhibitor, demonstrated potent early antiviral activity at 4 and 12 weeks when combined with the standard regimen of pegylated interferon plus ribavirin in previously untreated patients with HCV genotype 1, investigators reported at the at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna. |
|
